Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

ctively, based on weighted average shares outstanding of 17.6 million and 17.5 million, respectively.

Cash equivalents and short-term investments were approximately $57.0 million at September 30, 2009, compared to $13.4 million at June 30, 2009. The increase reflects the receipt of a $48.8 million upfront payment from Astellas received in July 2009.

Stephen Ghiglieri, CFO, commented, "The third quarter of 2009 represents the first time we have reported quarterly revenue, which marks a milestone for NeurogesX. Our balance sheet is also strongly positioned with $57 million in cash, cash equivalents and short term investments. Consistent with our spending guidance for 2009, we are continuing our conservative focus in advance of our upcoming PDUFA date. As a result of that focus, we have been investing in commercialization activities that require long lead times, such as setting up the distribution channel, that are necessary to implement now to be ready for our targeted first half 2010 launch. Major investments, such as sales force deployment, are still being deferred pending FDA approval of Qutenza. We are also exploring strategies to further strengthen our balance sheet ahead of a potential U.S. Qutenza launch."

Development Update

NeurogesX is advancing its planning for NGX-1998 and expects to re-initiate clinical development activities in 2010.

Conference Call Details

The Company will hold its quarterly conference call today at 9:00 a.m. ET (6:00 a.m. PT) to discuss third quarter 2009 results.

To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). To access the live web cast please visit the Investor Relations section on the corporate web site at http://www.neurogesx.com.

A replay of the conference call will be available beginning November 6, 2009 at 7:30 p.m. ET (4:30 p.m. PT) and endi
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  Prima Biomed Ltd. (NASDAQ: PBMD ) a ... a leader in the development of immunotherapeutic products for ... CVac data from the Phase II CAN-003 ovarian cancer ... clinically meaningful improvement in Overall Survival ("OS") over standard ... In the group of second remission patients (n=20), the ...
(Date:5/21/2015)... 21, 2015 W. R. Grace ... facility in Worms, Germany has received good manufacturing ... of the International Pharmaceutical Excipient Council (IPEC) Foundation. ... produce its SYLOID® FP brand of pharmaceutical grade ... following the Curtis Bay, Maryland (USA) and Sorocaba, ...
(Date:5/21/2015)... , May 20, 2015 Research and ... the addition of the "2015 Global Survey ... their offering. The primary goal of ... flow cytometry instruments and reagents. Key information the ... the selection of flow cytometers, predominantly used applications ...
(Date:5/20/2015)... SAN FRANCISCO, Calif. , May 20, 2015 ... VCYT ) today presented preliminary data demonstrating the ... distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial ... The findings suggest the classifier,s potential to help ... surgery to resolve ambiguity in IPF diagnosis – ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Global Survey on Flow Cytometry Adoption Trends 2015 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5
... researchers have developed a new strategy to overcome one ... physics. , What they,ve discovered could eventually aid high-temperature ... materials. , In 2008, the Defense Advanced Research Projects ... ambitious problem: trap atoms inside a light crystal -- ...
... (NYSE Amex:, SVA ), a leading developer and provider of vaccines ... twelve month,periods ended December 31, 2008. , , Full ... sales increasing 39% year-over-year to $46.5, ... 2008, up from 5.12 million in, ...
... Jivan announced today that it will provide ... and expression. Leveraging Jivan,s industry-leading bioinformatics infrastructure ... Jivan will provide "bioinformatics for the ... targeted sequencing with mRNA capture arrays, mRNA ...
Cached Biology Technology:Physicists discover important step for making light crystals 2Physicists discover important step for making light crystals 3Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 2Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 3Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 4Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 5Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 6Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 7Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 8Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 9Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 10Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 11Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 12Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 13Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 14Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 15Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 16Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 17Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 18Jivan Focuses on Solutions for Transcriptome Sequencing 2
(Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... of the Excellence Initiative have been made. Following ... proposals for the three funding lines by international ... German Science Council and the Deutsche Forschungsgemeinschaft (DFG, ... has awarded funding to 21 graduate schools, 20 ...
... commentary in the December 2007 issue of Infection ... a global initiative by the World Health Organization ... hygiene in health care. The commentary is part ... Human Development. An international collaboration organized by the ...
... SEATTLE An international team of researchers led ... has discovered two genes linked to a disabling ... and progressive disease in which some or all ... also validated the association of two genes implicated ...
Cached Biology News:Decisions on the second round of the Excellence Initiative announced 2Decisions on the second round of the Excellence Initiative announced 3Decisions on the second round of the Excellence Initiative announced 4Hand hygiene initiative aims to decrease healthcare-associated infection in developing countries 2Study reveals 2 genes linked to disabling arthritis 2Study reveals 2 genes linked to disabling arthritis 3
... of seven reduced, denatured proteins (equine myoglobin, ... muscle GAPDH, bovine muscle actin, BSA, and ... from 4.5 to 8.5 and molecular weights ... standards provide calibrated references for the pI ...
... gel adaptors, 24 glass tubes (1.5 mm ... The PROTEAN II xi cell and PROTEAN ... to perform a variety of separations,* including ... preparative, and gradient PAGE as well as ...
The PROTEAN II xi multi-cell 2-D conversion kit converts the PROTEAN II xi multi-cell to the PROTEAN II XL multi-cell for a wider format cell that accepts 17 to 18 cm IPG strips....
StemSep Anti-Phycoertherin Tetrameric Antibody Complexes, 2 mL for labeling 1x10 9 cells. Cross-linking Reagent for StemSep Separations of Cells Labeled with PE-conjugated Antibody....
Biology Products: